Objectives: This study was carried out to explore the possible anti-inflammatory effect of ibudilast on acetic acid-induced colitis in rats. Methods: Fifty adult Wistar rats were separated into 5 groups, including the control group, acetic acid group, acetic acid + vehicle, acetic acid + sulfasalazine (100 mg/kg/day)group, and acetic acid + ibudilast (30 mg/kg/day) group. Colitis was induced in rats by the inter-rectal installation of 2 ml of 4% (v/v) acetic acid. Sulfasalazine and ibudilast were administered orally for ten days after 2 hours of induction. Results: The treatment with ibudilast significantly reduced disease activity index (DAI), macroscopic colonic scores (MAC), and histopathological changes induced by acetic acid. Also, ibudilast markedly decreased the expression of proinflammatory markers (TNF-α and IL-1β) in colonic tissue. Moreover, ibudilast inhibited myeloperoxidase (MPO) enzyme activity that was increased by acetic acid. Conclusion: Therefore, ibudilast may have a therapeutic effect in the management of ulcerative colitis.
1 January 2026 in Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
Background: Ulcerative colitis is a persistent mucosal inflammation of the bowel that impacts a high portion of the population worldwide. It often presents with symptoms of severe diarrhea, weight reduction, and perianal bleeding. Objective: To investigate the potential anti-inflammatory effects of azilsartan on dextran sulfate-induced ulcerative colitis in rats. Methods: Forty healthy adult albino rats were divided into 4 groups, as follows: the normal control group, the DSS group, DSS+ prednisolone (10 mg/kg/day) group, and DSS+azilsartan (10 mg/kg/day) group. The colitis induction was prompted in rats by administering 3% DSS in drinking water for 7 days. Results: The administration of azilsartan notably decreased edema index, spleen index, macroscopic changes scores, and microscopic changes scores that were produced by DSS. Additionally, azilsartan markedly reduced the proinflammatory cytokine expression, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in colon tissue. Furthermore, azilsartan significantly attenuated oxidative stress in colonic tissue by decreasing up-regulated myeloperoxidase (MPO) enzyme activity and increasing down-regulated catalase antioxidant activity. Conclusions: Azilsartan may have an effective role in the treatment of ulcerative colitis.
5 May 2024 in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has been documented all over the world. Currently, limited evidence exists concerning the protec¬tion afforded by the COVID-19 vaccination against reinfection with SARS-CoV-2. This case-control study was per¬formed in order to assess the association between COVID-19 vaccination and SARS-CoV-2 reinfection in the Babil Province; the study used an electronic questionnaire. The infected patients were 115 (aged ≥18 years) and were confirmed by a positive PCR and/or a CT scan, they were either fully vaccinated or not with a second dose of a (Pfizer, AstraZeneca, or Sinopharm) vaccine before the reinfection date, and they were compared with 300 control partici¬pants. The study’s findings revealed that the unvaccinated individuals had 4.5 times the odds of reinfection compared to those who were fully vaccinated, without preference for the manufacturer of the vaccine. The conclusion suggests that getting fully vaccinated against COVID-19 can significantly reduce the likelihood of reinfection, can enhance overall protection, and can minimize the risk of future infections.